Semaglutide vs Tirzepatide UK 2026: The Two Most Talked-About Weight Loss Drugs
When comparing semaglutide vs tirzepatide UK 2026, it’s clear these two medications dominate conversation in weight management clinics. Two GLP-1-based medications dominate conversation in UK weight management clinics in 2026: semaglutide (sold as Wegovy for weight loss, Ozempic for type 2 diabetes) and tirzepatide (sold as Mounjaro). Understanding the difference — and which is likely to suit your needs — requires looking at how they work, what the clinical data shows, and what the practical differences are. For more information on GLP-1 agonists, you can visit Wikipedia. You can also read our latest guides for more weight loss tips.
Medical disclaimer: This article is informational only. Semaglutide and tirzepatide are prescription medications. Do not take either without medical supervision. Always consult a qualified healthcare professional before starting any medication for weight loss.
How They Work: Similar Goal, Different Mechanisms
Semaglutide is a GLP-1 receptor agonist — it mimics the naturally occurring glucagon-like peptide-1 hormone, which reduces appetite, slows gastric emptying, and improves blood sugar regulation. Semaglutide activates one receptor type (GLP-1).
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 receptor AND the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. This dual action is believed to provide additional metabolic benefits beyond what GLP-1 agonism alone achieves.
Think of it as tirzepatide hitting two targets where semaglutide hits one.
What the Clinical Evidence Shows
SURMOUNT trials (tirzepatide):
The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed participants using tirzepatide 15mg weekly achieved a mean weight loss of 22.5% of body weight over 72 weeks. At 10mg, weight loss was 21.4%; at 5mg, 16.0%.
STEP trials (semaglutide):
The STEP-1 trial for semaglutide 2.4mg showed a mean weight loss of 14.9% of body weight over 68 weeks.
Direct comparison:
The SURMOUNT-5 trial (completed 2024, results available in 2025) directly compared tirzepatide 10mg/15mg against semaglutide 2.4mg. Results showed tirzepatide produced approximately 47% more weight loss than semaglutide — confirming the advantage seen in indirect comparisons.
Headline: tirzepatide appears more effective for weight loss in head-to-head comparison. However, individual responses vary significantly, and the “better” medication depends on a patient’s specific health profile, tolerability, and needs.
Side Effect Profiles: What to Expect
Both medications share a similar side effect profile, predominantly gastrointestinal:
- Nausea (most common, particularly during dose escalation)
- Vomiting
- Diarrhoea or constipation
- Fatigue during dose escalation
- Reduced appetite (desirable, but can be excessive in some patients)
Does tirzepatide have worse side effects?
The clinical data suggests comparable tolerability. Nausea may be slightly more frequent with tirzepatide in some studies, but discontinuation rates due to adverse events were similar across trials. Individual variation is the dominant factor.
Both medications use a gradual dose escalation protocol specifically to minimise gastrointestinal side effects — dose increases happen every 4 weeks.
Availability in the UK in 2026
Semaglutide (Wegovy):
- Licensed for weight management in the UK by the MHRA
- Available on NHS through specialist weight management services for qualifying patients (BMI ≥35 with weight-related condition, or BMI ≥30 for some services)
- Available privately through clinics and online services
- Broadly available in 2026 after supply constraints largely resolved
Tirzepatide (Mounjaro):
- Licensed in the UK for type 2 diabetes (Mounjaro brand) and now for weight management
- Available on NHS in some specialist services
- More widely available through private prescription in 2026
- Broadly available; supply has improved since initial launch period
Which Should You Ask Your Doctor About?
Consider semaglutide if:
- You have type 2 diabetes or prediabetes (Ozempic for T2D has longer clinical history)
- You’re accessing treatment through NHS specialist services (Wegovy has been commissioned longer)
- You’ve already started semaglutide and are responding well
Consider tirzepatide if:
- You’re starting fresh and want to use the data on effectiveness
- Your primary goal is maximum weight loss
- You can access it through a private clinic or GP
Both are effective. The choice should ultimately be made with your prescribing clinician based on your full health picture, not brand comparisons alone.
FAQ
Q: Can I switch from semaglutide to tirzepatide?
A: Switching is possible under medical supervision. Clinicians typically advise a wash-out period or careful dose titration when switching between GLP-1 class medications. Do not switch without medical guidance.
Q: Is tirzepatide available on the NHS for weight loss?
A: Access is expanding but inconsistent across NHS trusts. Specialist weight management services are the primary NHS route. Many UK patients access tirzepatide through private prescription.
Q: Which drug is cheaper in the UK?
A: Costs vary by clinic and supply. Private prescription costs for both have changed as supply has stabilised. As a rough guide in 2026, monthly costs for tirzepatide and semaglutide at maintenance doses are broadly comparable at private clinics — typically £150–£250/month.
Q: Do you regain weight when you stop taking these medications?
A: Clinical data shows that weight regain occurs when GLP-1 medications are discontinued, as the appetite-suppressing effect ends. Long-term treatment or a structured transition to sustained lifestyle changes is typically recommended by prescribers.
Q: Are these medications safe for everyone?
A: No. Both semaglutide and tirzepatide are contraindicated in patients with a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, and certain other conditions. A full medical history assessment is required before prescribing.